Andrew Dahl Sells 568 Shares of Edwards Lifesciences (NYSE:EW) Stock

Edwards Lifesciences Corporation (NYSE:EW) SVP Andrew Dahl sold 568 shares of the business’s stock in a transaction that occurred on Friday, May 29th. The stock was sold at an average price of $86.08, for a total transaction of $48,893.44. Following the sale, the senior vice president owned 15,334 shares of the company’s stock, valued at approximately $1,319,950.72. This represents a 3.57% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available through the SEC website.

Edwards Lifesciences Trading Up 0.5%

EW traded up $0.45 during trading on Friday, hitting $86.41. 7,265,912 shares of the company’s stock were exchanged, compared to its average volume of 4,843,172. The firm has a market cap of $49.76 billion, a P/E ratio of 45.96, a price-to-earnings-growth ratio of 2.17 and a beta of 0.87. The stock has a 50 day moving average price of $81.66 and a 200 day moving average price of $82.98. The company has a current ratio of 4.42, a quick ratio of 3.63 and a debt-to-equity ratio of 0.06. Edwards Lifesciences Corporation has a 1 year low of $72.30 and a 1 year high of $88.28.

Edwards Lifesciences (NYSE:EW) last announced its earnings results on Thursday, April 23rd. The medical research company reported $0.78 earnings per share for the quarter, beating the consensus estimate of $0.73 by $0.05. The business had revenue of $1.65 billion during the quarter, compared to the consensus estimate of $1.60 billion. Edwards Lifesciences had a net margin of 17.39% and a return on equity of 15.19%. The business’s quarterly revenue was up 16.7% compared to the same quarter last year. During the same period in the prior year, the firm earned $0.64 earnings per share. Edwards Lifesciences has set its FY 2026 guidance at 2.950-3.050 EPS and its Q2 2026 guidance at 0.700-0.760 EPS. As a group, analysts expect that Edwards Lifesciences Corporation will post 3 EPS for the current fiscal year.

Analysts Set New Price Targets

A number of research firms have commented on EW. Weiss Ratings reiterated a “hold (c)” rating on shares of Edwards Lifesciences in a research note on Monday, April 20th. Truist Financial set a $90.00 price objective on shares of Edwards Lifesciences and gave the stock a “hold” rating in a report on Friday, April 24th. BTIG Research raised their target price on shares of Edwards Lifesciences from $98.00 to $100.00 and gave the company a “buy” rating in a research note on Friday, April 24th. UBS Group reissued a “neutral” rating and set a $94.00 target price on shares of Edwards Lifesciences in a research note on Wednesday, February 4th. Finally, The Goldman Sachs Group reaffirmed a “buy” rating and issued a $95.00 price objective (down from $108.00) on shares of Edwards Lifesciences in a research note on Wednesday, February 11th. Three equities research analysts have rated the stock with a Strong Buy rating, sixteen have given a Buy rating and nine have issued a Hold rating to the company’s stock. According to data from MarketBeat, the stock presently has a consensus rating of “Moderate Buy” and a consensus target price of $95.65.

Institutional Trading of Edwards Lifesciences

Several institutional investors have recently made changes to their positions in EW. Level Four Advisory Services LLC grew its position in Edwards Lifesciences by 3.7% in the third quarter. Level Four Advisory Services LLC now owns 3,301 shares of the medical research company’s stock worth $257,000 after acquiring an additional 119 shares in the last quarter. Colonial Trust Co SC lifted its stake in shares of Edwards Lifesciences by 0.4% in the third quarter. Colonial Trust Co SC now owns 32,196 shares of the medical research company’s stock worth $2,504,000 after buying an additional 120 shares during the last quarter. Evermay Wealth Management LLC lifted its stake in shares of Edwards Lifesciences by 4.0% in the fourth quarter. Evermay Wealth Management LLC now owns 3,304 shares of the medical research company’s stock worth $282,000 after buying an additional 128 shares during the last quarter. Rehmann Capital Advisory Group raised its stake in Edwards Lifesciences by 2.1% during the 4th quarter. Rehmann Capital Advisory Group now owns 6,399 shares of the medical research company’s stock valued at $546,000 after purchasing an additional 130 shares during the last quarter. Finally, Howard Capital Management Inc. raised its stake in Edwards Lifesciences by 3.3% during the 3rd quarter. Howard Capital Management Inc. now owns 4,136 shares of the medical research company’s stock valued at $322,000 after purchasing an additional 132 shares during the last quarter. 79.46% of the stock is currently owned by institutional investors and hedge funds.

Edwards Lifesciences Company Profile

Edwards Lifesciences is a medical technology company focused on products and therapies for structural heart disease and critical care monitoring. The company designs, develops and manufactures prosthetic heart valves and related delivery systems used in both surgical and minimally invasive (transcatheter) procedures. Its portfolio addresses a range of valvular conditions, with an emphasis on technologies that enable transcatheter aortic valve replacement (TAVR) as an alternative to open-heart surgery.

In addition to transcatheter heart valves—including the widely recognized SAPIEN family—Edwards offers surgical tissue valves and ancillary devices used by cardiac surgeons, interventional cardiologists and hospital teams.